Voya Investment Management LLC Buys 26,148 Shares of Kymera Therapeutics, Inc. $KYMR

Voya Investment Management LLC grew its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 9.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 296,062 shares of the company’s stock after purchasing an additional 26,148 shares during the quarter. Voya Investment Management LLC’s holdings in Kymera Therapeutics were worth $33,097,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of Kymera Therapeutics in the 2nd quarter valued at about $635,067,000. Merck & Co. Inc. purchased a new stake in Kymera Therapeutics in the second quarter worth about $88,544,161. Bank of America Corp DE purchased a new position in shares of Kymera Therapeutics in the 2nd quarter valued at approximately $43,378,000. Braidwell LP boosted its position in shares of Kymera Therapeutics by 12.0% during the second quarter. Braidwell LP now owns 378,163 shares of the company’s stock valued at $43,364,000 after purchasing an additional 40,604 shares in the last quarter. Finally, Fisher Asset Management LLC grew its stake in Kymera Therapeutics by 2,438.6% in the third quarter. Fisher Asset Management LLC now owns 323,219 shares of the company’s stock worth $36,133,000 after purchasing an additional 310,487 shares during the period.

Kymera Therapeutics Price Performance

Shares of NASDAQ:KYMR opened at $119.39 on Friday. The company has a market capitalization of $10.19 billion, a P/E ratio of -32.98 and a beta of 2.04. Kymera Therapeutics, Inc. has a 1-year low of $63.69 and a 1-year high of $142.92. The firm’s 50 day simple moving average is $117.58 and its two-hundred day simple moving average is $100.33.

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.26) by ($0.06). Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 22.39%. The firm had revenue of $1.35 million for the quarter, compared to the consensus estimate of $3.28 million. During the same quarter in the previous year, the business earned ($0.94) earnings per share. The firm’s revenue for the quarter was up .0% on a year-over-year basis. On average, sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -3.88 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on KYMR. TD Cowen upgraded shares of Kymera Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Wells Fargo & Company increased their price target on shares of Kymera Therapeutics from $116.00 to $151.00 and gave the stock an “overweight” rating in a research note on Thursday, August 27th. Guggenheim lifted their price target on shares of Kymera Therapeutics from $135.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, August 31st. Bank of America increased their target price on Kymera Therapeutics from $123.00 to $144.00 and gave the stock a “buy” rating in a research note on Monday, September 14th. Finally, Royal Bank Of Canada raised their price target on shares of Kymera Therapeutics from $112.00 to $116.00 and gave the company a “sector perform” rating in a research report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $139.16.

Check Out Our Latest Analysis on Kymera Therapeutics

Insiders Place Their Bets

In other Kymera Therapeutics news, CEO Nello Mainolfi sold 30,000 shares of the firm’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the sale, the chief executive officer directly owned 666,568 shares of the company’s stock, valued at $75,855,438.40. This trade represents a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Brian Adams sold 6,371 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $116.83, for a total value of $744,323.93. Following the completion of the transaction, the insider owned 50,254 shares in the company, valued at $5,871,174.82. The trade was a 11.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 15.98% of the company’s stock.

Kymera Therapeutics Company Profile

(Free Report)

Kymera Therapeutics, Inc. is a clinical-stage biotechnology company developing medicines that selectively remove disease-causing proteins from cells. Its approach, known as targeted protein degradation, uses the body’s natural protein-disposal system and is designed to address targets that may be difficult to reach with conventional drugs. The company’s research and development programs include small-molecule protein degraders for conditions involving immune and inflammatory pathways, as well as cancer.

Further Reading

Want to see what other hedge funds are holding KYMR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report).

Institutional Ownership by Quarter for Kymera Therapeutics (NASDAQ:KYMR)

Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.